ERBB2 and breast carcinoma: While therapy using HER2-inhibition is genuinely successful in primary or advanced HER2-positive breast cancer, BRAF inhibition is often undertaken by downstream mutations leading to time-dependent relapses (Finn et al., 2012; Pernas and Tolaney, 2019).